Scarica l'app Stockscreener
6.74
0.15%
-0.010
Pre-mercato:
6.75
0.010
+0.15%
Precedente Chiudi:
$6.75
Aprire:
$6.53
Volume 24 ore:
145.05K
Relative Volume:
0.81
Capitalizzazione di mercato:
$166.59M
Reddito:
$251.00K
Utile/perdita netta:
$-83.87M
Rapporto P/E:
-1.9645
EPS:
-3.4309
Flusso di cassa netto:
$-79.34M
1 W Prestazione:
+30.62%
1M Prestazione:
+16.81%
6M Prestazione:
+128.47%
1 anno Prestazione:
+135.66%
Intervallo 1D:
$6.38
$6.80
Intervallo di 1 settimana:
$4.74
$7.1371
Portata 52W:
$1.47
$7.7542
Artiva Biotherapeutics Inc Stock (ARTV) Company Profile
Nome
Artiva Biotherapeutics Inc
Settore
Industria
Telefono
(858) 267-4467
Indirizzo
5505 MOREHOUSE DRIVE, SAN DIEGO
Compare ARTV vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARTV
Artiva Biotherapeutics Inc
|
6.74 | 166.59M | 251.00K | -83.87M | -79.34M | -3.4309 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Artiva Biotherapeutics Inc Stock (ARTV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-11 | Ripresa | H.C. Wainwright | Buy |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Iniziato | Jefferies | Buy |
| 2024-08-13 | Iniziato | Needham | Buy |
| 2024-08-13 | Iniziato | TD Cowen | Buy |
| 2024-08-13 | Iniziato | Wedbush | Outperform |
Mostra tutto
Artiva Biotherapeutics Inc Borsa (ARTV) Ultime notizie
ARTV Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Artiva Biotherapeutics (NASDAQ:ARTV) Rating Increased to Hold at Wall Street Zen - Defense World
Artiva Biotherapeutics Inc. (ARTV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ARTV Technical Analysis & Stock Price Forecast - Intellectia AI
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
BZ2704 Forecast — Price Prediction for 2026. Should I Buy BZ2704? - Intellectia AI
Artiva Biotherapeutics (ARTV) Expected to Announce Earnings on Monday - MarketBeat
ARTV SEC FilingsARTIVA BIOTHERAPEUTICS INC 10-K, 10-Q, 8-K Forms - stocktitan.net
If You Invested $1,000 in ARTIVA BIOTHERAPEUTICS INC (ARTV) - Stock Titan
FFAIW Should I Buy - Intellectia AI
POWWP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
LEGT Should I Buy - Intellectia AI
Market Rankings: Can PROP deliver consistent EPS growth2026 Analyst Calls & Risk Controlled Swing Alerts - baoquankhu1.vn
Should I add Artiva Biotherapeutics Inc stock to my portfolio2026 Big Picture & Community Verified Trade Signals - baoquankhu1.vn
02652 Should I Buy - Intellectia AI
TOLL Should I Buy - Intellectia AI
GRABW Should I Buy - Intellectia AI
Wedbush Maintains Artiva Biotherapeutics (ARTV) Outperform Recommendation - MSN
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Sees Significant Decrease in Short Interest - MarketBeat
Artiva Biotherapeutics, Inc. (ARTV) Receives a Buy from Jefferies - The Globe and Mail
Research Analysts Issue Forecasts for ARTV Q1 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Artiva Biotherapeutics, Inc. (ARTV) and Edgewise Therapeutics (EWTX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Artiva Biotherapeutics, Inc. (ARTV) and Clinigence Holdings (NUTX) - The Globe and Mail
Artiva Biotherapeutics (NASDAQ:ARTV) Given Buy Rating at Needham & Company LLC - Defense World
Artiva Biotherapeutics, Inc. 2025 Annual Report: Business Overview, Risk Factors, and Strategic Outlook - Minichart
Artiva Biotherapeutics' (ARTV) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Artiva: Sufficient Cash Runway to 2027 Supports Buy Rating Ahead of Key 2026 RA Efficacy Readouts - TipRanks
ARTV: AlloNK shows promise in refractory RA as clinical and financial milestones approach in 2026 - TradingView
Artiva Biotherapeutics 10-K: Revenue $0.0M, Net Loss $(83.9)M — Cash $108.0M - TradingView
ARTV: 2025 net loss widened to $83.9M as R&D spending increased; cash runway extends into Q2 2027 - TradingView
Artiva Biotherapeutics posts 2025 results, prepares for RA clinical data in early 2026 - Traders Union
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights - marketscreener.com
Artiva Biotherapeutics (ARTV) grants CFO 220,000 RSUs as inducement - stocktitan.net
Growth Value: Is Stantec Inc on track to beat earningsWeekly Volume Report & Expert Curated Trade Ideas - baoquankhu1.vn
What insider trading reveals about Artiva Biotherapeutics Inc. stock2026 Price Swings & Advanced Swing Trade Entry Plans - Naître et grandir
Dow Update: Does Artiva Biotherapeutics Inc have consistent dividend growthWeekly Gains Summary & Technical Buy Zone Confirmation - baoquankhu1.vn
Artiva Biotherapeutics Pivots to Rheumatoid Arthritis at TD Cowen, Teases 2026 RA Data Update - MarketBeat
Latigo Biotherapeutics Appoints Neha Krishnamohan as Chief Financial Officer and Chief Business Officer - biospace.com
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewswire
Artiva Biotherapeutics appoints Thad Huston as chief financial officer - Investing.com Australia
Artiva Biotherapeutics appoints Thad Huston as chief financial officer By Investing.com - Investing.com South Africa
Artiva Biotherapeutics Appoints Thad Huston as Chief Financial Officer - TipRanks
Artiva Biotherapeutics, Inc. Appoints Thad Huston as Principal Financial Officer and Principal Accounting Officer, Effective from February 18, 2026 - marketscreener.com
Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant - The Globe and Mail
Artiva Biotherapeutics Announces Appointment Of Thad Huston As CFO - TradingView
Artiva Biotherapeutics Announces Appointment of Thad Huston - GlobeNewswire
Is Artiva Biotherapeutics Inc. on track to beat earningsJuly 2025 Retail & Daily Profit Maximizing Tips - mfd.ru
Can Artiva Biotherapeutics Inc. keep up with sector leaders2025 Institutional Moves & AI Driven Stock Movement Reports - mfd.ru
Will Artiva Biotherapeutics Inc. benefit from rate cutsJuly 2025 Weekly Recap & Consistent Profit Alerts - mfd.ru
Artiva Biotherapeutics appoints pharma veteran Elaine Sorg to board By Investing.com - Investing.com India
Artiva Biotherapeutics Inc Azioni (ARTV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):